• Mirum Pharmaceuticals Inc (NASDAQ: MIRM) has acquired Satiogen Pharmaceuticals Inc in a cash and stock deal.

• The deal consideration includes 841,792 shares, 199,993 of which are subject to the achievement of a milestone, and approximately $2.8 million in cash.

• Mirum will wholly own the Satiogen subsidiary, which will receive a 2% royalty.

• Satiogen was an existing licensing partner for Livmarli (maralixibat) oral solution and volixibat. Through the transaction, Mirum obtained all Satiogen licensing payments and Satiogen-owned intellectual property relating to Livmarli and volixibat.

• The transaction will reduce total licensing royalty obligations for Livmarli and volixibat to high single-digit to low teens.

• As of March 31, 2022, Mirum held cash, cash equivalents, restricted cash equivalents, and investments of $239.9 million.

• Price Action: MIRM shares are down 2.11% at $25.04 during the market session on the last check Monday.

See more from Benzinga

• Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

• Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.